PHTS is granted an International Classification of Diseases (ICD) Code! - Click here for more information.
Rob is Chief Drug Development Scientist at Cancer Research UK’s Centre for Drug Development. At CRUK Rob has overseen the delivery of over 25 drug candidates into first-in-human clinical trials including cell therapies, vaccines, antibodies and small molecules. In addition to his translational teams, Rob has management responsibility for CRUK scientists at the CRUK-AstraZeneca antibody discovery laboratory in Cambridge and chairs the target selection committee for this alliance. Rob has previously held scientific leadership positions in therapeutic areas outside of cancer, including metabolic and inflammatory diseases, and has a wide breadth of experience in strategic and operational business planning gained from working in the pharma (Glaxo, Rhone-Poulenc Rorer/Aventis), biotech and not-for-profit sectors. During his time at Prolifix, Rob led on the pre-clinical characterisation and early development of Belinostat, now an approved medicine for the treatment of peripheral T-cell lymphoma. Rob acts as a scientific advisor for a number of both non-commercial and commercial research organisations, lectures in drug development on several MSc courses and co-founded Duke Street Bio, an Immuno-oncology-focused drug discovery company.